Confounding Effects of Benign Lung Diseases on Non-Small Cell Lung Cancer Serum Biomarker Discovery

Table 2 Significant differences between lung cancer patients and nondiseased and diseased controls

m/z ratio	Cancer versus nondiseased controls (p value)	Cancer versus benign disease controls (p value)	Fold change (cancer/nondiseased controls)	Fold change (benign disease controls/nondiseased controls)
5,080	1.64E−08	0.071	1.74	1.43
15,140	5.20E−07	0.019	0.52	0.82
3,521	6.89E−07	0.091	2.23	1.50
6,672	9.09E−07	0.053	0.57	0.88
6,681	1.57E−06	0.071	0.57	0.87
14,690	3.02E−06	0.033	0.62	0.84
131,600	6.59E−06	0.049	0.67	0.86
17,090	6.98E−06	0.024	1.70	1.32
3,289	9.78E−06	0.175	2.39	1.50
4,213	1.52E−05	0.029	0.60	0.81

p values were calculated by Wilcoxon test and fold changes indicate the median of one cohort divided by the median of the other. Peaks in italics have been identified

ISSN: 1559-0275